SCHEMBL22320252

SCHEMBL22320252

COc1ccc2c(c1)C(CO[C]=O)c1ccccc1-2

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR2A P28223 2/20 0.40
CA1 P00915 1/20 0.40
CA2 P00918 1/20 0.40
GAA P10253 2/20 0.38
GPR3 P46089 1/20 0.38
FABP5 Q01469 1/20 0.38
HRH3 Q9Y5N1 1/20 0.37
MTNR1A P48039 1/20 0.37
MTNR1B P49286 1/20 0.37
TSHR P16473 1/20 0.36
HTT P42858 1/20 0.36
HSD17B1 P14061 1/20 0.36
HSD17B2 P37059 1/20 0.36
CYP19A1 P11511 1/20 0.36
MAPT P10636 1/20 0.36
CYP1A1 P04798 1/20 0.36
CYP1A2 P05177 1/20 0.36
CYP2E1 P05181 1/20 0.36
CYP3A4 P08684 1/20 0.36
CYP2C8 P10632 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7764 0.83 CA1 (0.53) HTR2ACA1CA2FABP5TSHR
SCHEMBL28678862 0.81 CA1 (0.40) HTR2ACA1CA2FABP5HRH3
SCHEMBL18055683 0.80 CA1 (0.42) HTR2ACA1CA2GPR3FABP5
SCHEMBL9449380 0.78 HRH3 (0.55) HTR2AGAAGPR3HRH3MTNR1A
SCHEMBL3056225 0.77 TTR (0.42) CA1CA2GAAFABP5KDM4E
SCHEMBL135438 0.76 CA1 (0.44) HTR2ACA1CA2FABP5HRH3
SCHEMBL3331520 0.76 PTPRC (0.42) CA1CA2GAAGPR3CYP19A1
Dimethylformamide SCHEMBL28310394 0.75 CA1 (0.43) HTR2ACA1CA2GPR3FABP5
SCHEMBL1934963 0.75 AKR1B1 (0.41) CA1CA2GAAFABP5TSHR
Hydrochloric Acid SCHEMBL8638272 0.74 HTR2A (0.48) HTR2AGAAGPR3HRH3HSD17B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3924369-A1 LONG-ACTING GLP-2 ANALOGS OPKO Biologics Ltd. (IL) 2021-12-22 EP claimed
CN-113710692-A Long-acting GLP-2 analogs OPKO生物科学有限公司 2021-11-26 CN claimed
WO-2020165900-A1 LONG-ACTING GLP-2 ANALOGS OPKO BIOLOGICS LTD. (IL) 2020-08-20 WO claimed
US-20200254065-A1 LONG-ACTING GLP-2 ANALOGS OPKO BIOLOGICS LTD. (IL) 2020-08-13 US claimed
EP-3924369-A1 LONG-ACTING GLP-2 ANALOGS OPKO Biologics Ltd. (IL) 2021-12-22 EP disclosed
CN-113710692-A Long-acting GLP-2 analogs OPKO生物科学有限公司 2021-11-26 CN disclosed
WO-2020165900-A1 LONG-ACTING GLP-2 ANALOGS OPKO BIOLOGICS LTD. (IL) 2020-08-20 WO disclosed
US-20200254065-A1 LONG-ACTING GLP-2 ANALOGS OPKO BIOLOGICS LTD. (IL) 2020-08-13 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20200254065-A1 LONG-ACTING GLP-2 ANALOGS GLP1R, GIPR, GCGR HTR2A 342/4885CA1 4827/4885CA2 4454/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.